Indian Journal of Medical Microbiology IAMM  | About us |  Subscription |  e-Alerts  | Feedback |  Login   
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size
 Home | Ahead of Print | Current Issue | Archives | Search | Instructions  
Users Online: 2638 Official Publication of Indian Association of Medical Microbiologists 
 ~   Next article
 ~   Previous article
 ~   Table of Contents

 ~   Similar in PUBMED
 ~  Search Pubmed for
 ~  Search in Google Scholar for
 ~   Citation Manager
 ~   Access Statistics
 ~   Reader Comments
 ~   Email Alert *
 ~   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded59    
    Comments [Add]    

Recommend this journal


Year : 1992  |  Volume : 10  |  Issue : 1  |  Page : 3-15

Current Status Of H. Influenzae Type B Vaccines

Correspondence Address:
Mathuram Santosham

Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Haemophilus influenzae type b (Hib) is the leading cause of meningitis in children below 5 years of age. Majority of cases of Hib occur in infants below 2 years of age. Until recently the only vaccine available against this disease contained the pure polysaccharide (PRP) of (Hib-PRP Vaccine). The Hib-PRP vaccine was demonstrated to be efficacious in infants above 18 months of age but not below that age. This product was licensed for routine use in the U.S.A. for children aged 24 months or more. Recently a hyper immune globulin termed bacterial polysaccharide immune globulin (BPIG) was prepared by immunizing adult donors with Hib-PRP, meningococcal and pneumococcal vaccines. BPIG has been demonstrated to prevent Hib infections when it is administered to infants at 4-month intervals. However, BPIG has not been licensed for routine use in the U.S.A.A number of new Hib conjugate vaccines have also been developed in the last few years by covalently linking the Hib-PRP to different carrier proteins. Four different Hib conjugate vaccines have undergone clinical trials in the U.S.A. Two of these vaccines, HbOC (Hib capsular oligosaccharide linked to CRM 197) and Hib-OMPC (Hib capsular polysaccharide linked to Neisseria meningitides outer membrane protein complex) have been demonstrated to protect infants aged 2 months or more from Hib disease. Both HbOC and Hib-OMPC are currently licensed for routine use in the U.S.A. The widespread use of these vaccines should have a substantial impact in reducing morbidity and mortality from Hib disease.


Print this article     Email this article

2004 - Indian Journal of Medical Microbiology
Published by Wolters Kluwer - Medknow

Online since April 2001, new site since 1st August '04